BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34599979)

  • 1. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial.
    Bachert C; Han JK; Desrosiers MY; Gevaert P; Heffler E; Hopkins C; Tversky JR; Barker P; Cohen D; Emson C; Martin UJ; Shih VH; Necander S; Kreindler JL; Jison M; Werkström V
    J Allergy Clin Immunol; 2022 Apr; 149(4):1309-1317.e12. PubMed ID: 34599979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.
    Desrosiers M; Diamant Z; Castelnuovo P; Hellings PW; Han JK; Peters AT; Silver J; Smith SG; Fuller A; Sousa AR; Chan RH; Gevaert P;
    Int Forum Allergy Rhinol; 2024 Jan; 14(1):18-31. PubMed ID: 37345861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps.
    Hopkins C; Mullol J; Khan AH; Lee SE; Wagenmann M; Hellings P; Fokkens W; Msihid J; Nair R; Kamat S; Nash S; Radwan A; Jacob-Nara JA; Deniz Y; Rowe PJ
    Otolaryngol Head Neck Surg; 2024 Apr; 170(4):1173-1182. PubMed ID: 38156522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP.
    Rosso C; De Corso E; Conti V; Nitro L; Saibene AM; Parazzini E; Rinaldo R; De Pascalis S; Arnone F; Centanni S; Montuori C; D'Auria LM; Felisati G; Pipolo C
    Eur Arch Otorhinolaryngol; 2024 Jun; 281(6):3017-3023. PubMed ID: 38347197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE.
    Mullol J; Lund VJ; Wagenmann M; Han JK; Sousa AN; Smith SG; Mayer B; Chan RH; Fokkens WJ
    Rhinology; 2024 Jun; 62(3):320-329. PubMed ID: 38217844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial.
    Emson C; Han JK; Hopkins C; Asimus S; Cann JA; Chain D; Wu Y; Reddy Y; McCrae C; Cohen D; Kreindler JL; Werkström V; Jison M; Wagenmann M; Bachert C
    Br J Clin Pharmacol; 2024 May; ():. PubMed ID: 38715387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of an oral CRTH2 antagonist (AZD1981) in the treatment of chronic rhinosinusitis with nasal polyps in adults: A randomized controlled clinical trial.
    Price CPE; Guo A; Stevens WW; Cousens L; Vu TT; Suh LA; Erickson KA; Conley D; Grammer LC; Kern RC; Tan BK; Kato A; Schleimer RP; Smith SS; Welch KC; Peters AT
    Clin Exp Allergy; 2022 Jul; 52(7):859-867. PubMed ID: 35524339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.
    Gevaert P; Mullol J; Saenz R; Ko J; Steinke JW; Millette LA; Meltzer EO
    Ann Allergy Asthma Immunol; 2024 Mar; 132(3):355-362.e1. PubMed ID: 37951571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2).
    Palmer JN; Adappa ND; Chandra RK; Davis GE; Mahdavinia M; Messina J; Ow RA; Patel ZM; Peters AT; Sacks H; Schlosser RJ; Sindwani R; Soler ZM; White AA; Wise SK; Mahmoud RA
    J Allergy Clin Immunol Pract; 2024 Apr; 12(4):1049-1061. PubMed ID: 38244014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study protocol: the biologics in severe chronic rhinosinusitis with nasal polyps survey.
    Favier V; Daveau C; Carsuzaa F; Fieux M; Vandersteen C; Castillo L; Papon JF; de Gabory L; Saroul N; Verillaud B; Rumeau C; Jankowski R; Michel J; de Bonnecaze G; Lecanu JB; Coste A; Béquignon E; Malard O; Mortuaire G
    BMJ Open; 2024 May; 14(5):e083112. PubMed ID: 38749694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP.
    Guo CL; Liu FF; Wang DY; Liu Z
    Curr Allergy Asthma Rep; 2023 Dec; 23(12):703-713. PubMed ID: 37987873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety profile of mepolizumab in chronic rhinosinusitis with nasal polyps: Real life data in a tertiary care.
    Galletti C; Ciodaro F; Barbieri MA; Gambino F; Ferrisi MG; Portelli D; Catalano N; Spina E; Freni F; Galletti B
    Am J Otolaryngol; 2024; 45(4):104329. PubMed ID: 38696895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benralizumab in Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps: The Real-World, Multi-Country RANS Observational Study.
    Le TT; Emmanuel B; Katial R; Tran TN; Kwiatek JJ; Cohen DS; Daniel SR; Cao Y; Shih VH; Melcón MG; Devouassoux G; Pelaia G;
    J Asthma Allergy; 2024; 17():313-324. PubMed ID: 38595692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of budesonide intrapolyp injection in the management of type 2 chronic rhinosinusitis with nasal polyps: a randomised clinical trial.
    Elzayat S; Elgendy A; Lasheen H; El-Deeb ME; Aouf MM; Gehad I
    J Laryngol Otol; 2024 Apr; 138(4):416-424. PubMed ID: 37781760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps.
    Kemp P; van der Lans RJL; Otten JJ; Adriaensen GFJPM; Benoist LBL; Cornet ME; Hoven DR; Rinia B; Verkest V; Fokkens WJ; Reitsma S
    Rhinology; 2024 Apr; 62(2):202-207. PubMed ID: 37999634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Efficacy of Budesonide as Intrapolyp Injection Agent in the Management of Type 2 CRSwNP.
    Elzayat S; Lasheen H; Gehad I; El-Deeb ME; Soltan I; Aouf MM; Elgendy A
    Laryngoscope; 2024 May; 134(5):2085-2092. PubMed ID: 37916779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis.
    Pelaia C; Crimi C; Benfante A; Caiaffa MF; Campisi R; Candia C; Carpagnano GE; Carrieri I; D'Amato M; Detoraki A; Barbaro MPF; Lombardo N; Macchia L; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Ricciardi L; Scichilone N; Scioscia G; Spadaro G; Tondo P; Uletta Lionetti S; Valenti G; Vatrella A; Crimi N; Pelaia G
    Respirology; 2024 Jun; ():. PubMed ID: 38847185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-thymic stromal lymphopoietin monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps (DUBHE): Rationale and design of a multicenter, randomized, double-blind, placebo-controlled study.
    Shen S; Xian M; Yan B; Lan F; Wang C; Zhang L
    Asia Pac Allergy; 2024 Mar; 14(1):26-31. PubMed ID: 38482462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab's impact on nasal citology: Real life experience after 1 year of treatment.
    Gelardi M; Giancaspro R; Quaranta VN; La Gatta E; Ruzza A; Cassano M
    Am J Otolaryngol; 2024; 45(4):104275. PubMed ID: 38574514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukotriene antagonists in nasal polyposis: a meta-analysis and systematic review.
    Wentzel JL; Soler ZM; DeYoung K; Nguyen SA; Lohia S; Schlosser RJ
    Am J Rhinol Allergy; 2013; 27(6):482-9. PubMed ID: 24274224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.